STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) reports today that the ninth and
final patient was recruited to the phase Ia study of MIV-818 in
patients with advanced liver cancer. Based on data from phase Ia,
the initial dose of MIV-818 for the phase Ib study has been
determined at 200 mg / week. The dosage is given as 40 mg / day for
five days.
The phase I study with MIV-818, evaluating safety, tolerability
and pharmacokinetics, consists of two parts: Phase Ia is an
interpatient study while phase Ib has a classic 3 + 3 intrapatient
dose-escalating design. A recommended dose for phase II will be
based on the data in the phase Ib study. Medivir has previously
reported that the intended liver-directed effect of MIV-818 could
be verified already in the analysis of data from the first six
patients. Efficacy data from the complete phase Ia study will be
presented next year at a scientific conference.
"The initial data observed in the phase I study support our view
that MIV-818 has the potential to provide a clear and much needed
improvement in treatment for patients with liver cancer," said Dr.
Uli Hacksell, CEO of Medivir. "MIV-8I8 is the most advanced drug
candidate in a series of proprietary and wholly owned prodrugs that
we intend to develop for the treatment of various cancer
indications."
For further information, please contact:
Uli Hacksell, CEO
Medivir AB
phone: +46 (0)8 5468 3100
About MIV-818
MIV-818 is a pro-drug designed to selectively treat liver
cancers and to minimize side effects. It has the potential to
become the first liver-targeted, orally administered drug to
benefit patients with HCC and other forms of liver cancer. A phase
I study in patients with liver cancer is ongoing.
About liver cancer
Liver cancer is the third leading cause of cancer-related deaths
worldwide and hepatocellular carcinoma (HCC) is the most common
cancer that arises in the liver. Although existing therapies for
advanced HCC are capable of extending the lives of patients,
treatment benefits are low while death rates remain high. HCC is a
very diverse disease with multiple cancer cell types and without
specific mutations seen in other tumor types. This has contributed
to the lack of success of molecularly targeted agents in HCC. The
limited overall benefit, taken together with the poor overall
prognosis for patients with intermediate and advanced HCC, results
in a large unmet medical need.
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The company is investing in
indication areas where available therapies are limited or missing
and there are great opportunities to offer significant improvements
to patients. Collaborations and partnerships are important parts of
Medivir's business model and the drug development is conducted
either by Medivir or in partnership. Medivir's share (ticker: MVIR)
is listed on Nasdaq Stockholm's Small Cap list.
www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-reports-last-patient-recruited-to-the-phase-ia-study-of-miv-818-in-liver-cancer-patients-and,c2966709
The following files are available for download:
|
https://mb.cision.com/Main/652/2966709/1145931.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/medivir-reports-last-patient-recruited-to-the-phase-ia-study-of-miv-818-in-liver-cancer-patients-and-initial-dose-determined-for-phase-ib-300959752.html
SOURCE Medivir
